Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  WuXi Biologics (Cayman) Inc.    2269   KYG970081090

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
01/15/2021 01/18/2021 01/19/2021 01/20/2021 01/21/2021 Date
103 104.6 110.8 116.6 114.4 Last
15394070 8223990 23046950 19108140 17214550 Volume
-1.62% +1.55% +5.93% +5.23% -1.89% Change
Financials
Sales 2020 5 403 M 835 M 835 M
Net income 2020 1 482 M 229 M 229 M
Net cash position 2020 4 624 M 715 M 715 M
P/E ratio 2020 264x
Yield 2020 -
Sales 2021 8 064 M 1 246 M 1 246 M
Net income 2021 2 108 M 326 M 326 M
Net cash position 2021 3 842 M 594 M 594 M
P/E ratio 2021 189x
Yield 2021 -
Capitalization 390 B 60 374 M 60 302 M
EV / Sales 2020 71,4x
EV / Sales 2021 47,9x
Nbr of Employees 5 694
Free-Float -
More Financials
Company
WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company’s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs.... 
Sector
-
Calendar
03/22Earnings Release
More about the company
Notations Surperformance© of WuXi Biologics (Cayman) Inc.
Trading Rating : Investor Rating :
More Ratings
All news about WUXI BIOLOGICS (CAYMAN) INC.
01/05WUXI BIOLOGICS (CAYMAN) : Major Shareholder Strikes $1.3 Billion Share Placement..
MT
2020WUXI BIOLOGICS CAYMAN : Bayer sells a facility at its Wuppertal site to WuXi Bio..
AQ
2020WUXI BIOLOGICS CAYMAN : Germany Unit Acquires Manufacturing Facility from Bayer
MT
2020HK stocks end lower as U.S. ban ramps up pressure on China
RE
2020WUXI BIOLOGICS CAYMAN : AC Immune and WuXi Biologics Strengthen Strategic Partne..
AQ
2020WUXI BIOLOGICS CAYMAN : AB2 Bio and WuXi Biologics Announce Collaboration to Acc..
AQ
2020China, Hong Kong stocks rise on strong quarterly earnings, financials boost
RE
2020WUXI BIOLOGICS CAYMAN : Shares Soar on Upbeat Revenue Guidance, China's Vaccine ..
DJ
2020ANTENGENE : Announces Collaboration with WuXi Biologics to Advance the Developme..
PR
2020WUXI BIOLOGICS CAYMAN : Plans Stock Split
DJ
2020WUXI BIOLOGICS CAYMAN : Proposed share subdivision
PU
2020Hong Kong shares slump as possible SMIC blacklisting sinks tech names
RE
2020WUXI BIOLOGICS (CAYMAN) INC. : half-yearly earnings release
2020WUXI BIOLOGICS (CAYMAN) INC. : Press Release
CO
2020WUXI BIOLOGICS (CAYMAN) INC. : Half-year results
CO
More news
News in other languages on WUXI BIOLOGICS (CAYMAN) INC.
2020WUXI BIOLOGICS (CAYMAN) INC. : publication des résultats semestriels
2020WUXI BIOLOGICS (CAYMAN) INC. : Veröffentlichung des Halbjahresergebnisses
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | 2269 | KYG970081090 | MarketScreener
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 82,03 CNY
Last Close Price 95,37 CNY
Spread / Highest target 22,4%
Spread / Average Target -14,0%
Spread / Lowest Target -52,1%
EPS Revisions
Managers and Directors
NameTitle
Zhi Sheng Chen Chief Executive Officer & Executive Director
Ge Li Non-Executive Chairman
Shao Hua Lu-Wong Chief Financial Officer
Weichang Zhou Executive Director, Chief Technology Officer & EVP
Edward Hu Non-Executive Director